Vizient (R) is proud to announce that the Vizient Clinical Data Base was recognized by Modern Healthcare as one of the Best in Business of 2025. The entire list of winners can be found in the Jan. 12, ...

Cytovale(R) , a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, today announced that it was ...

Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at the Iowa College of ...

Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...

What antibiotic should I use to treat this patient’s Klebsiella pneumoniae? It’s resistant to carbapenems, and there’s a ...

UNR med students and faculty work to provide free medical services to patients who are uninsured, underinsured or facing ...

New investors include Pfizer Ventures and Apricot Capital with proceeds to advance pipeline and global expansionVibrant’s ...

Detailed price information for Cellectis S.A. ADR (CLLS-Q) from The Globe and Mail including charting and trades.

First MIRACLE trial unblinding expected Q1 2026; Global trial now spans nine countries– Investigator-Initiated (IIT) funded pancreatic and ...

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has ...

In this conversation, Tina Eden, R.N., CEO of Virginia Gay Hospital, and Jacinda Bunch, Ph.D., R.N., assistant professor at ...

Positive Phase 3 HERIZON-GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal ...